Immunome, Inc. Cash and Restricted Cash
Immunome, Inc. (IMNM) had Cash and Restricted Cash of $217.92 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $217.92M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $582.90M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $653.69M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $272.85M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $217.92M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $582.90M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $653.69M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $272.85M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $144.09M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $257.71M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $143.45M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $155.67M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $165.43M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $269.82M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $98.78M 10-K · filed 2026-03-03 |
| 2023-09-30 | $90.74M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $38.52M 10-Q · filed 2024-08-12 |
| 2023-03-31 | $44.52M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $20.42M 10-K · filed 2025-03-19 |
| 2022-09-30 | $27.18M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $34.75M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $42.98M 10-Q · filed 2023-05-05 |
| 2021-12-31 | $49.33M 10-K · filed 2024-03-28 |
| 2021-09-30 | $56.34M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $59.93M 10-Q · filed 2022-08-05 |
| 2021-03-31 | $36.38M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $39.87M 10-K · filed 2023-03-16 |
| 2020-09-30 | $6.84M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $9.89M 10-Q · filed 2021-08-16 |
| 2020-03-31 | $1.37M 10-Q · filed 2021-05-12 |
| 2019-12-31 | $2.64M 10-K · filed 2022-03-28 |
| 2019-09-30 | $860.00K 10-Q · filed 2020-11-16 |
| 2018-12-31 | $1.70M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |